pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-190b |
Genomic Coordinates | chr1: 154193665 - 154193743 |
Description | Homo sapiens miR-190b stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |
---|---|
Mature miRNA | hsa-miR-190b |
Sequence | 11| UGAUAUGUUUGAUAUUGGGUU |31 |
Evidence | Not_experimental |
Experiments | |
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | MKL2 | ||||||||||||||||||||
Synonyms | MRTF-B, MRTFB, NPD001 | ||||||||||||||||||||
Description | MKL1/myocardin like 2 | ||||||||||||||||||||
Transcript | NM_014048 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on MKL2 | |||||||||||||||||||||
3'UTR of MKL2 (miRNA target sites are highlighted) |
>MKL2|NM_014048|3'UTR 1 CGTCACAGATTTCTTTTCTGAGAGTTGATGAGGTTTAAGAACATGAAGATTCTAAAAGGTCAGTTTTTAGAGATAGATCT 81 ATAGTTGCATTGTTGCAATCAAAATATGTTGTCACAGAAAGAATAGGTGGAAGGTCATAGCCTGGAACCCAAGTTTGAAA 161 ACATTTCATTGTGTTCAGTAGTGAATTTCTACAGTTTAACATAGCACAGGGCCTTCTGAAAATCGCACTTGTCAAAGACG 241 ACTCATCTATTTCTCCAGACTTCAGTAAAGAATGAAAAGTACCTTTAGATAAAAACAAAGAAGAGTAATATATGCAGCAC 321 AGTGACGTTAGGATTCTGGTAATTAACTACATTTAAATCTCTGGTCACTTTAAGACCCTAAATAAAAGGCAGACAGCTCC 401 ACTCAAAAACTAAGGCTGATGTGAGGGAGGTGAGAGGTCACTGCACTTGGTACTTCCTAGAGACGGCCGGAGCCAGGCCC 481 AAGACACAGCAGAGGTCAAAGGCAGTGGAGAGCCTTGGCCAGTTCAGTGACAGCTTCTGGCTGAAGACTTTTGGTTCTAT 561 TCAGAAACCTGTGTCGTTTTTTTGGTGTTGTAGTTTATTTTGTGATTTTTTGGAATCGTACTTTATATTTCCAAATTTAA 641 ATTTAAATGCAAGATCTTTCAACATAAACAGAAGATACCTACAAAATACTGTCAGAAGTCCAGGTATACTGATAACACTG 721 AAAATTCTATTAGCAACCTTCTGGGTTGGTTAGATTGATTTTAATGTATATATTAGACATTTGTATGTATGCTCTGACAT 801 TGTGATTTGTACAGCCTACGCTGGGGTAAGGAAATGGGTATCCAAGGTCCTACTTTTTTAATAGCTCGAATATTTCTAGA 881 GTACTTGAGCCACATGTATTTCTGTATTTAAAGAATTGCTGACTAACTTTCAGGTAACCAGACCCATCTCAAAGAACCAA 961 GAAAAGGCTTTAGCATGAAATATCTTTCTGAGCTGGCGAGTTAGAAGAATGGAAGGTAAGGGGAAGGTCTGTCATCTACC 1041 CAGGACATTCCCATGATGAGTACAGGTCAGATTGTGCCACAAGGTGGGCCTCCACGTCCCTGCCCTGGCCCTCTTTCTTC 1121 TGTCACTAACCCTGGTTATCATTTTACAGGCTTGTAACTGGATATTCTACCAGAGCTCTCACTATATTGTCAAGCCTAAG 1201 ATTGAAAAACTGGAGGCTTTATTAGTGTTTTTATATAGAAAACAGTTATTACATATGTGTTAAGTCATTTCTTAAGAATT 1281 TTCTAAAATGCCAACTATCACAGGATTATTTCAAGCTAGTCATTGAGGTATATGACAAAATGTAAATAACAAAAAACTGA 1361 AATCTACCAAAAGAGCATGGAGATTTTTCTTAAATAATAATATTGTGCTCTCCACCTCACCCTTGTGTAAACCCTCAGGT 1441 CAGGTTGGTTCCCCTGGGTCACAAAATGGTAAATGTTCCATACTGACATGCCGGAGGCAGCCTGACCCGTTATTTGGAAA 1521 GAATTTGTGAATTATTTCTGGGTTTGTGTTTTGCCTAAGAGCTGATCTTATTTCTGATTTGTGTGTGTGTGGTTTATAAA 1601 TTTTACTACGTGTAACAAAAGTCTGCTTTTCCAGCATGAGCACACTGGAGCCCTCTGCTCACTGGCACTTCCTGACTCAA 1681 AGGCACTAACAGTGCTCATGTGCCTTCCAGACGGTTCAAGGCAGAGGCCACTGTGCTCAGTGTAGTCTGTGATGAATAGT 1761 TTAAGTGTTCAGAAATTGGTAAACCAACACACGGGATACAATAACTCTCTGTTAACCAGAACACCGTCATTTGACCAAGC 1841 CCTACAAGAGTTTACCACACTAGATGTTCTGTGAATCCTCGAGTCAGTTCCATTGAGAGGGGCCTGTCTCCAGGGCCAGG 1921 CTATTTACTTGGGAAAGTATTTTTCTTACAGTTCTTGGCCACAGTTTTTTTGCTGAGGGTTTCTGTCTGGGCCTATCAGG 2001 TCCATACTTAGACCCTGAGCATCTTCTTCATTCAGATTTGAATGGCTTATTAAATTAGCACCAAATATCAGTGGGACTGT 2081 AGAAGGTAACCGAACACTAGTACCATTGACTCTCGTTGAATAACTTTATATTTCCATAATCCTGAATTGTGTAGATAGTT 2161 TTCTAGCTCTCGGGTCCCTTTATTGCTTTTTAAAATAGGGTTTGAAACATGCCACAGGAAGGTTGCTCTCCAAAAATACA 2241 CAGTGCAGTGCAAGAAAATGCTATCTCATTGGCCTACTCTCCTATGAATTGCTAAAGTGCCCACTTCACATATGTGTTTA 2321 AACCTTTATAAACCAGTATTTCACTTTTAAAAAGACAAGGCATCTCTACCCATTAACTCTGCAAGCCACTCCACTTGCAC 2401 CATTCCGCTTGACCCTCCTCTCTCCTGGCTTGGGTCACCAGCCAGGCACCTGTGACACGAGTGCTGCTCTCCAGGATCTC 2481 CACTACATGTTCCAGGTTGGAGTGAGGACGCGCTATGTGCTCACACTCATGTGACATGACCAAAGATGATACTCTGTAAA 2561 CAAGGCCCTTCTGACCGGACTCAGTGCGTGTGATGGTGAGTGCAATGAGGAAGGGTGGATATTGACTAAAGACTGGTTGT 2641 TGTTGTTGTTTAGGTTAGTGTCACAGCCATTACAGCACAAGTCAAAGTCGCCAGTTGAATTTTCATTATGCACGTGTGTG 2721 GTTTAAGCAGTGGTACTGTTGTATATCATATTGTAAAGTATCATACTGCCAAGAAAATAACTCCTAGAAAGGCATTATCT 2801 CACATCCCCATCTTACTTTCCTACATGTTCTCAAAACACAGTAGTACCAGCCTTACCTTTCTGCTGTATGTAGATAGTCA 2881 GATCATCCTACTGGGGGTGGGATGAATTTAAAAGTTATACCAAAATTTCTGTAAAGTCTTTGAAAGTCTAGGAGTAGGTG 2961 GTCATCTTGTACATTTCAGCAAAGCATCCACTAGGAAACCTCATAGGACAGTGTTAGTGGTTCACGTTCTAGTGTTTTTC 3041 CTGAAATGTGCAATCTACTGTATAGTATTGCCACATAATTGTACATAGATGTATTCTGAATTTGTGGAATTTCTTGCTTA 3121 GATACTATTGTGTTTGTTTCATATGAATATTTTTGTAATTCTAAAAGAGATCTTATTTAAATTTCCTTTTTAAAAGCCGC 3201 ATGGTTCTGTGATCCATGTAACTGACACTTTTTGGCTTTCAGTGCTGTTTAGAAACAGTGGCAAAGGCAGGGTGGTGCTG 3281 CCTGCAAGCTGCTGCCTATGGAAGGCAAAGTCATAGTAATGAGATAGCACCTCTGAACTGTGCAGTCAGCATACCCTGAG 3361 TGATGGCTCAGGGGCGCACTACCTATTTTGTCACCAGAGCTGACTCAGGCTTCCTGGACCCTCAACCCCAGATCATTCCA 3441 GGCAGCATAGCTTTCTTCACAGTCCTTTCAGAATTCCCAGGCTGAAATCAGCCATAGCAGTTGACAAAACAGCTATCCCC 3521 ACAAGTGATGAGATAGTCCCTTTACTGTCCTCAAATGGACTTGGCCTTAGAGACGTGGTAAAGCACTTTGGCAGGGTTTA 3601 AAATATTTGTGAGAAGCCCACATTTCAGTATACATCCTCACTGGCTTCCATGCACCCACCTGACGGTAGCCTCACAGAAG 3681 TCCTGGCTGTCACTCAGGTGGGGAGCTCATGGTGCCGCTGGGGACTTTTTAGAGAAATGTAAAGAGAATAGCTATTCAGT 3761 GTCTACTAGCAGAGCAACATGTGTCAATTTAACCAAATTCACAAATAACCCTCCATTTTTCAATATCTGCTACTGTAAAC 3841 ATGAATATTGAATACTGACAAGAGAATACCCATACAAATCGTCCCACCGCCCTAGAGGCCACAGAATTAGCCCAAAATTA 3921 TCAAAGAACATTAACTGGAAGGTCAGGTTTTTCAAGGAACATAGCTTACAAATGCATCAGTGTGTATCTGGAGAGCATCC 4001 TAACTGCATTTCAACTCATCTTTTAAGTGATTTCAGTCAAAACTGGAAAACAACTAAGATGTAGTAATTTTTTTTTCCTG 4081 GTTCAAACCTTCAATAACTTGCTCATTCAGCAGTCTCTCTGAGCTACATTTTTATTTGTAAAGTGACTCTGTCTGCATGG 4161 CAATGAGCAGGTGCGTGTTTTTTCCACATTCGCCCTTTCTTGCAGTATCCAGGGAAACACATCATTACAAAGGGTTTCTA 4241 CCTGAAATCTTTCATGGAAGGCCTACAATTCGAAAAGCTGCACATGTTTACAGAAGAGCTCTTACCCTCCATGCAAACAC 4321 TTTGCTCTGTGGTGTCACAGCTTTGTGACAATAAGATGGCAATCTCGGATCTACAAGGTGCTGTCGGGAATCAAATAAAA 4401 TATGTTATCAGAGATATCATCACATCTATAGTGTTTAACAGAGCTTTATGCCAACTACTAAGACAAAGCTTTAACAAAGT 4481 TTATAGAATACTGAAACTCGTAACAATTACCTCTCTACGTGATGCTGTAAGGAATCTTGCTAATTTGGTAGGAAGAGGAA 4561 GCATTTAGGAAAGGGTTTAGTATCTACCAAAAGTACTTGACCTCAAGTAACCAATAGTAATGCAAACTTGCTTTAAAGGA 4641 ACCAAAGGCATTGCCAAGTATTTGCCAAAAGGAGGCACTTTTTATTTAAAATTTGAGACTAATGAGATCTCAAAAATCAG 4721 CCCCAAAAAGGTATTATCCATTTAAGGTTATAATTTTCACTAAGATGTAGATATTTCTCTTATTGTTTTCATGTAAAATA 4801 GTATAGAGTTGTTTTGTTGGTTTAAGAGTAACATTCAGTAGTAATACAAAGTTTTTTTTCTATGTAGAAATTAGTTTTCT 4881 TTTCTTGCTTGCAATAGAAATGCAATGTGATAGGTGTTTCTCTTCTTATTTTCATTGTCACATTATGTCTTAGCATCTCA 4961 CTTTATGAAAAAAAGGAGAAAGATACCAATCTACAGAGCCCTGCTTGTTGAAGCACTAGTTTAATCAACAAAAAATTATG 5041 GCAATCGGGGGTCCATTCATCTATTGCCTTTATGTTGTTTTTTAAAAGAAAAACCATGATGCCTTTGTATTTGCTGTTTG 5121 CACCCCTGAAATCAATTCCATATCATGTTTGAATGCCATACATTTTGCACATGTACTGTACATAAGTAATGCATACTGTA 5201 TTTTTATATGTGTGCACATTTATCATCAGATCTTTTGTACATAGTGGCAGTATTGTAGCTGATCGGGAAATGTTTGATAT 5281 CTCAGCAATTTTGCATTTTTGTGTCTCAAATAAAAGACATTTTGATGTACTATGAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
CLIP-seq Support 1 for dataset GSM4903833 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_a |
Location of target site | NM_014048 | 3UTR | AUGUUUGAAUGCCAUACAUUUUGCACAUGUACUGUACAUAAGUAAUGCAUACUGUAUUUUUAUAUGUGUGCACAUUUAUCAUCAGAUCUUUUGUACAUA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000318282.5 | 3UTR | AUUCCAUAUCAUGUUUGAAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
60 hsa-miR-190b Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT054581 | IGF1 | insulin like growth factor 1 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT066966 | ATXN7L3B | ataxin 7 like 3B | ![]() |
![]() |
2 | 2 | ||||||
MIRT192449 | SPRED1 | sprouty related EVH1 domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT250414 | TNRC6A | trinucleotide repeat containing 6A | ![]() |
![]() |
2 | 2 | ||||||
MIRT306294 | KLHL24 | kelch like family member 24 | ![]() |
![]() |
2 | 2 | ||||||
MIRT355845 | SGMS2 | sphingomyelin synthase 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT437770 | MTMR6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT437771 | MTMR6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT437772 | Mtmr6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT444672 | CDKL2 | cyclin dependent kinase like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446389 | PCDHB11 | protocadherin beta 11 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446634 | SDC3 | syndecan 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449410 | TRIM5 | tripartite motif containing 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449560 | GPC5 | glypican 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT469928 | PTPRJ | protein tyrosine phosphatase, receptor type J | ![]() |
![]() |
2 | 6 | ||||||
MIRT473736 | MAP3K9 | mitogen-activated protein kinase kinase kinase 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT474210 | LDHA | lactate dehydrogenase A | ![]() |
![]() |
2 | 2 | ||||||
MIRT474583 | KLF6 | Kruppel like factor 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT476732 | FOXN2 | forkhead box N2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT478455 | DAB2 | DAB2, clathrin adaptor protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT495327 | ADAMTS8 | ADAM metallopeptidase with thrombospondin type 1 motif 8 | ![]() |
![]() |
2 | 4 | ||||||
MIRT498615 | MTRNR2L10 | MT-RNR2-like 10 | ![]() |
![]() |
2 | 12 | ||||||
MIRT501734 | OVOL1 | ovo like transcriptional repressor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT501849 | MTRNR2L8 | MT-RNR2-like 8 | ![]() |
![]() |
2 | 14 | ||||||
MIRT504678 | CYGB | cytoglobin | ![]() |
![]() |
2 | 4 | ||||||
MIRT506517 | MSANTD4 | Myb/SANT DNA binding domain containing 4 with coiled-coils | ![]() |
![]() |
2 | 6 | ||||||
MIRT507984 | BCL2L13 | BCL2 like 13 | ![]() |
![]() |
2 | 4 | ||||||
MIRT508444 | ZNF608 | zinc finger protein 608 | ![]() |
![]() |
2 | 4 | ||||||
MIRT511366 | IL6ST | interleukin 6 signal transducer | ![]() |
![]() |
2 | 4 | ||||||
MIRT520515 | TRA2B | transformer 2 beta homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT524571 | CALML4 | calmodulin like 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT531896 | INVS | inversin | ![]() |
![]() |
2 | 4 | ||||||
MIRT533916 | TATDN2 | TatD DNase domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT537503 | FAM13B | family with sequence similarity 13 member B | ![]() |
![]() |
2 | 2 | ||||||
MIRT541689 | CCDC160 | coiled-coil domain containing 160 | ![]() |
![]() |
2 | 8 | ||||||
MIRT544419 | ZNF460 | zinc finger protein 460 | ![]() |
![]() |
2 | 4 | ||||||
MIRT544615 | CSDE1 | cold shock domain containing E1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT545076 | IL7R | interleukin 7 receptor | ![]() |
![]() |
2 | 2 | ||||||
MIRT545849 | ZNF264 | zinc finger protein 264 | ![]() |
![]() |
2 | 4 | ||||||
MIRT547436 | MED4 | mediator complex subunit 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT550157 | ZNF223 | zinc finger protein 223 | ![]() |
![]() |
2 | 4 | ||||||
MIRT553948 | STAMBP | STAM binding protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT554395 | SERP1 | stress associated endoplasmic reticulum protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT555667 | PGAM4 | phosphoglycerate mutase family member 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT564193 | PM20D2 | peptidase M20 domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566792 | MKL2 | MKL1/myocardin like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566843 | LRRC58 | leucine rich repeat containing 58 | ![]() |
![]() |
2 | 2 | ||||||
MIRT572516 | KIAA0232 | KIAA0232 | ![]() |
![]() |
2 | 2 | ||||||
MIRT607428 | NOTCH2NL | notch 2 N-terminal like | ![]() |
![]() |
2 | 10 | ||||||
MIRT627779 | RAB30 | RAB30, member RAS oncogene family | ![]() |
![]() |
2 | 2 | ||||||
MIRT635159 | ENO4 | enolase family member 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT642159 | ADCYAP1R1 | ADCYAP receptor type I | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT646205 | DUSP10 | dual specificity phosphatase 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT657007 | KCNMB4 | potassium calcium-activated channel subfamily M regulatory beta subunit 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT665817 | TMEM161B | transmembrane protein 161B | ![]() |
![]() |
2 | 2 | ||||||
MIRT667488 | MAP3K2 | mitogen-activated protein kinase kinase kinase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT707098 | ZNF850 | zinc finger protein 850 | ![]() |
![]() |
2 | 2 | ||||||
MIRT708719 | PTPLAD2 | 3-hydroxyacyl-CoA dehydratase 4 | ![]() |
1 | 1 | |||||||
MIRT735521 | HUS1 | HUS1 checkpoint clamp component | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT736644 | AGPAT3 | 1-acylglycerol-3-phosphate O-acyltransferase 3 | ![]() |
![]() |
2 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|